Harvard Bioscience (HBIO) Operating Expenses (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Operating Expenses data on file, last reported at $13.4 million in Q1 2026.

• On a quarterly basis, Operating Expenses fell 78.31% year-over-year to $13.4 million in Q1 2026; TTM through Mar 2026 was $50.1 million, a 52.68% decrease from a year earlier, with the FY2025 full-year figure at $98.5 million, up 61.52% from the prior year.
• Operating Expenses for Q1 2026 stood at $13.4 million, up from $12.5 million in the prior quarter.
• Over the last five years, Operating Expenses for HBIO reached as high as $61.9 million in Q1 2025 and fell as low as $11.8 million in Q3 2025.
• Historically, Operating Expenses has averaged $17.9 million across 5 years, with a median of $15.7 million in 2023.
• Across the five-year window, Operating Expenses soared 262.75% in 2025 and slumped 78.31% in 2026, its largest moves.
• Year by year, Operating Expenses stood at $16.3 million in 2022, then declined by 1.52% to $16.0 million in 2023, then fell by 12.73% to $14.0 million in 2024, then slipped by 10.99% to $12.5 million in 2025, then increased by 7.67% to $13.4 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $13.4 million in Q1 2026, $12.5 million in Q4 2025, and $11.8 million in Q3 2025.